AIMS/HYPOTHESIS: Reduced beta cell mass due to increased beta cell apoptosis is a key defect in type 2 diabetes. Islet amyloid, formed by the aggregation of human islet amyloid polypeptide (hIAPP), contributes to beta cell death in type 2 diabetes and in islet grafts in patients with type 1 diabetes. In this study, we used human islets and hIAPP-expressing mouse islets with beta cell Casp8 deletion to (1) investigate the role of caspase-8 in amyloid-induced beta cell apoptosis and (2) test whether caspase-8 inhibition protects beta cells from amyloid toxicity. METHODS: Human islet cells were cultured with hIAPP alone, or with caspase-8, Fas or amyloid inhibitors. Human islets and wild-type or hIAPP-expressing mouse islets with or without caspase-8 expression (generated using a Cre/loxP system) were cultured to form amyloid. Caspase-8 and -3 activation, Fas and FLICE inhibitory protein (FLIP) expression, islet beta cell and amyloid area, IL-1β levels, and the beta:alpha cell ratio were assessed. RESULTS: hIAPP treatment induced activation of caspase-8 and -3 in islet beta cells (via Fas upregulation), resulting in apoptosis, which was markedly reduced by blocking caspase-8, Fas or amyloid. Amyloid formation in cultured human and hIAPP-expressing mouse islets induced caspase-8 activation, which was associated with Fas upregulation and elevated islet IL-1β levels. hIAPP-expressing mouse islets with Casp8 deletion had comparable amyloid, IL-1β and Fas levels with those expressing hIAPP and Casp8, but markedly lower beta cell apoptosis, higher beta:alpha cell ratio, greater beta cell area, and enhanced beta cell function. CONCLUSIONS/ INTERPRETATION: Beta cell Fas upregulation by endogenously produced and exogenously applied hIAPP aggregates promotes caspase-8 activation, resulting in beta cell apoptosis. The prevention of amyloid-induced caspase-8 activation enhances beta cell survival and function in islets.
AIMS/HYPOTHESIS: Reduced beta cell mass due to increased beta cell apoptosis is a key defect in type 2 diabetes. Islet amyloid, formed by the aggregation of human islet amyloid polypeptide (hIAPP), contributes to beta cell death in type 2 diabetes and in islet grafts in patients with type 1 diabetes. In this study, we used human islets and hIAPP-expressing mouse islets with beta cell Casp8 deletion to (1) investigate the role of caspase-8 in amyloid-induced beta cell apoptosis and (2) test whether caspase-8 inhibition protects beta cells from amyloid toxicity. METHODS:Human islet cells were cultured with hIAPP alone, or with caspase-8, Fas or amyloid inhibitors. Human islets and wild-type or hIAPP-expressing mouse islets with or without caspase-8 expression (generated using a Cre/loxP system) were cultured to form amyloid. Caspase-8 and -3 activation, Fas and FLICE inhibitory protein (FLIP) expression, islet beta cell and amyloid area, IL-1β levels, and the beta:alpha cell ratio were assessed. RESULTS:hIAPP treatment induced activation of caspase-8 and -3 in islet beta cells (via Fas upregulation), resulting in apoptosis, which was markedly reduced by blocking caspase-8, Fas or amyloid. Amyloid formation in cultured human and hIAPP-expressing mouse islets induced caspase-8 activation, which was associated with Fas upregulation and elevated islet IL-1β levels. hIAPP-expressing mouse islets with Casp8 deletion had comparable amyloid, IL-1β and Fas levels with those expressing hIAPP and Casp8, but markedly lower beta cell apoptosis, higher beta:alpha cell ratio, greater beta cell area, and enhanced beta cell function. CONCLUSIONS/ INTERPRETATION: Beta cell Fas upregulation by endogenously produced and exogenously applied hIAPP aggregates promotes caspase-8 activation, resulting in beta cell apoptosis. The prevention of amyloid-induced caspase-8 activation enhances beta cell survival and function in islets.
Authors: J Janson; W C Soeller; P C Roche; R T Nelson; A J Torchia; D K Kreutter; P C Butler Journal: Proc Natl Acad Sci U S A Date: 1996-07-09 Impact factor: 11.205
Authors: Clara Westwell-Roper; Derek L Dai; Galina Soukhatcheva; Kathryn J Potter; Nico van Rooijen; Jan A Ehses; C Bruce Verchere Journal: J Immunol Date: 2011-08-03 Impact factor: 5.422
Authors: C B Verchere; D A D'Alessio; R D Palmiter; G C Weir; S Bonner-Weir; D G Baskin; S E Kahn Journal: Proc Natl Acad Sci U S A Date: 1996-04-16 Impact factor: 11.205
Authors: K J Potter; A Abedini; P Marek; A M Klimek; S Butterworth; M Driscoll; R Baker; M R Nilsson; G L Warnock; J Oberholzer; S Bertera; M Trucco; G S Korbutt; P E Fraser; D P Raleigh; C B Verchere Journal: Proc Natl Acad Sci U S A Date: 2010-02-16 Impact factor: 11.205
Authors: S Zraika; R L Hull; J Udayasankar; K Aston-Mourney; S L Subramanian; R Kisilevsky; W A Szarek; S E Kahn Journal: Diabetologia Date: 2009-01-16 Impact factor: 10.122
Authors: Kathrin Maedler; Adriano Fontana; Frédéric Ris; Pavel Sergeev; Christian Toso; José Oberholzer; Roger Lehmann; Felix Bachmann; Andrea Tasinato; Giatgen A Spinas; Philippe A Halban; Marc Y Donath Journal: Proc Natl Acad Sci U S A Date: 2002-06-11 Impact factor: 11.205
Authors: Safia Costes; Chang-jiang Huang; Tatyana Gurlo; Marie Daval; Aleksey V Matveyenko; Robert A Rizza; Alexandra E Butler; Peter C Butler Journal: Diabetes Date: 2010-10-27 Impact factor: 9.461
Authors: Lucy Marzban; Alejandra Tomas; Thomas C Becker; Lawrence Rosenberg; Jose Oberholzer; Paul E Fraser; Philippe A Halban; C Bruce Verchere Journal: Diabetes Date: 2008-08-11 Impact factor: 9.461